Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

62 questions · 62 findings · 1 reviews · HIV/AIDS · Headline outcomes only

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 8 · 12.9%Low 24 · 38.7%Moderate 28 · 45.2%High 2 · 3.2%

An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers

HIV transmission at 6 months among those whose HIV diagnostic testing was negative within 96 hours of birth · HIV‐infected mothers and their breastfeeding infants

An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in HIV transmission at 6 months among those whose HIV diagnostic… compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).

1 finding from 1 review

An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers

Infant Mortality at 6 Months · HIV‐infected mothers and their breastfeeding infants

An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infant Mortality at 6 months compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).

1 finding from 1 review

An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers

HIV Transmission or Death at 6 months among those whose HIV diagnostic testing was negative within 96 hours of birth · HIV‐infected mothers and their breastfeeding infants

It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes HIV Transmission or Death at 6 months among those whose HIV… compared with an extended ZDV/3TC/ABC administered to mothers (very low certainty).

1 finding from 1 review

An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers

Infant Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants

An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infants with Grade 3/4 Severe Adverse Events compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).

1 finding from 1 review

An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers

Maternal mortality ‐ not reported · HIV‐infected mothers and their breastfeeding infants

An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in maternal Mortality at 6 months compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).

1 finding from 1 review

An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers

Maternal Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants

An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in mothers with any Grade 3/4 Severe Adverse Event compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).

1 finding from 1 review

An extended ZDV/3TC/LPV/r regimen administered to mothers vs an extended ZDV/3TC/ABC administered to mothers

Mothers with Severe Adverse Events Requiring Treatment Modification · HIV‐infected mothers and their breastfeeding infants

It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes mothers with Severe Adverse Events Requiring Treatment Modification compared with an extended ZDV/3TC/ABC administered to mothers (very low certainty).

1 finding from 1 review

An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants

HIV transmission at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · HIV‐infected mothers and their breastfeeding infants

An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in HIV transmission at 28 weeks among those whose diagnostic testing… compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants

Infant mortality at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · HIV‐infected mothers and their breastfeeding infants

An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in infant mortality at 28 weeks among those whose diagnostic testing… compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants

HIV transmission or death at 28 weeks among those whose diagnostic test was negative at 2 weeks · HIV‐infected mothers and their breastfeeding infants

An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in HIV transmission or death at 28 weeks among those whose diagnostic… compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants

Infants with Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants

An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in infants with Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).

1 finding from 1 review

An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants

Mothers with Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants

An extended antiretroviral regimen administered to mothers for 28… may leads to higher mothers with Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

HIV Transmission at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in HIV Transmission at 9 months among those whose HIV diagnostic… compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infant Mortality at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in infant Mortality at 9 months among those whose HIV diagnostic… compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

HIV Transmission at 24 months among those uninfected at birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in HIV Transmission at 24 months among those uninfected at birth compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

HIV Transmission or Death at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in HIV Transmission or Death at 9 months among those whose HIV… compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infant Mortality at 24 months among those uninfected at birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in infant Mortality at 24 months among those uninfected at birth compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

HIV Transmission or Death at 24 months among those uninfected at birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in HIV Transmission or Death at 24 months among those uninfected at birth compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… may leads to higher infants with any Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

It is very uncertain whether an extended NVP plus ZDV dual regimen administered to infants for 14… changes infants with Probably Related Severe Adverse Events compared with an extended NVP regimen administered to infants (very low certainty).

1 finding from 1 review